GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT-8 system and ePlex sample-to-answer systems are designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. At GenMark, we’re changing the diagnostics landscape, combining out-of-the-box thinkers and game-changing technology to revolutionize patient care.
Our work atmosphere is dynamic, fast-paced, and patient-focused. We encourage teamwork, while reinforcing the importance of individuality, and encouraging an entrepreneurial spirit. GenMark is not just a job – it’s a way of life. We also provide opportunities to volunteer in the community, participate in sports leagues, and enjoy company social events.
Culture is the cornerstone of what makes GenMark a special place to work. We are proud to embrace a culture of accountability in the work we do.
Company Growth (employees)
GenMark Diagnostics was founded in 2010 and is headquartered in Carlsbad, US
GenMark Diagnostics Office Locations
GenMark Diagnostics has offices in Carlsbad, Englewood, Chicago, Minneapolis and in 32 other locations
Carlsbad, US (HQ)
5964 La Pl Ct
Zug, CH
6 General-Guisan-Strasse
GenMark Diagnostics Financials and Metrics
GenMark Diagnostics Financials
GenMark Diagnostics's revenue was reported to be $49.3 m in FY, 2016 which is a 25% increase from the previous period.
USD
Revenue (FY, 2016) | 49.3 m |
Revenue growth (FY, 2015 - FY, 2016), % | 25% |
Gross profit (FY, 2016) | 29.6 m |
Gross profit margin (FY, 2016), % | 60% |
Net income (FY, 2016) | (50.6 m) |
EBIT (FY, 2016) | (49 m) |
Market capitalization (17-Oct-2017) | 389.8 m |
Cash (31-Dec-2016) | 16 m |
GenMark Diagnostics's current market capitalization is $389.8 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 27.4 m | 30.6 m | 39.4 m | 49.3 m |
Revenue growth, % | 12% | 29% | 25% | |
Cost of goods sold | 15.3 m | 19.7 m | ||
Gross profit | 24.1 m | 29.6 m |
| USD | Y, 2009 | Y, 2010 | Y, 2011 | Y, 2012 | Y, 2013 | Y, 2014 | Y, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|---|---|
Cash | 16.5 m | 51.3 m | 25.3 m | 51.3 m | 35.7 m | 36.9 m | 35.4 m | 16 m |
Inventories | 2.1 m | 2.1 m | 3.1 m | 3.1 m | ||||
Current Assets | 111.1 m | 78.1 m | 56 m | 58.4 m | ||||
PP&E | 8.6 m | 11.1 m | 11.4 m | 18.3 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (33.6 m) | (38.3 m) | (42.2 m) | (50.6 m) |
Depreciation and Amortization | 2.5 m | 2.7 m | 3.4 m | 3.9 m |
Accounts Receivable | (2.4 m) | (2 m) | (2.3 m) | (2.3 m) |
Inventories | (1.3 m) | (229 k) | (3.5 m) | (3.5 m) |
| Y, 2016 | |
|---|---|
Financial Leverage | 2.1 x |
GenMark Diagnostics Operating Metrics
| FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|
Patents Pending | 25 | 35 | 30 |
Patents Issued | 130 | 120 | 100 |
